​Peucedanum morisonii Besser (Dzungaria Hog's Fennel)

Peucedanum morisonii Besser (Dzungaria Hog's Fennel / Morison's Peucedanum)

Product Name: горичник Морисона, Peucedanum morisonii Besser, Morisons Haarstrang, peucedano de Morison, Peucedanum de Morison, ‏بيوسيدانوم موريسون‏, ผักชีล้อมมอริสัน, Morison tog‘aragi, Морисондун горичниги, Morison zirəsi, Морисон зираи, Morisono peletrūnas, Morisona sīļķe, Горичник Морісона, מוריסון פאוּסֵדָנוּם

Synonyms: Peucedanum alsaticum subsp. morisonii (Besser) Dostál, Dzungaria Hog's Fennel, Morison's Peucedanum, Morison's Hogfennel, Peucedanum cervaria var. morisonii (Besser) Thell., Peucedanum morisonii Besser ex DC, горичник Морисона, Morisons Haarstrang, Morison peucedanum, peucedano de Morison, Peucédanum de Morison ‏, ผักชีล้อมมอริสัน, народные: горичник, волосник

Parts used: roots, fruits (seeds), herb (aerial part), leaves, inflorescences.

Main indications for the use of Peucedanum morisonii: Chronic non-bacterial prostatitis, chronic pelvic pain syndrome, congestive prostatitis, chronic vesiculitis, urethroprostatic pain syndrome, mild neurogenic dysuria, initial stage vascular erectile dysfunction, prostatodynia, functional orchialgia.

Indications for the use of Peucedanum morisonii in mixtures and complexes: Chronic bacterial prostatitis, benign prostatic hyperplasia stage I–II, orchiepididymitis, chronic urethritis, post-infectious asthenozoospermia, pelvic venous congestion, mixed erectile dysfunction, chronic cystitis in men, chronic prostato-vesiculitis, prostatorrhea, prostatitis associated with metabolic syndrome, chronic pelvic myofascial dysfunction.

Main pharmacological properties of Peucedanum morisonii: anti-inflammatory, antispasmodic, analgesic, antimicrobial, antifungal, vasodilating, angioprotective, venotonic, antioxidant, mild sedative, adaptogenic, immunomodulatory, mild diuretic, mild choleretic, hepatoprotective, antiproliferative, potential 5-α-reductase inhibitor.

Dosage of Pharmaceutical Forms — Peucedanum morisonii

Powder — Peucedanum morisonii

Indications (Powder): Chronic non-bacterial prostatitis, chronic pelvic pain syndrome, congestive prostatitis, chronic vesiculitis, urethroprostatic pain syndrome, mild neurogenic dysuria, initial stage vascular erectile dysfunction, prostatodynia, functional orchialgia.

Standard Dosage (Powder): 300–400 mg orally 2 times a day before meals, course of 21–30 days.

Enhanced Dosage (Powder): 400–500 mg orally 2–3 times a day before meals for chronic prostatitis with pronounced pain syndrome, chronic prostato-vesiculitis, and pelvic venous congestion; course of 30–45 days.

Maximum Dosage (Powder): Up to 600 mg orally 3 times a day (up to 1.8 g/day) short-term up to 10 days for exacerbation of chronic pelvic pain syndrome or resistant non-bacterial prostatitis; further use only after clinical evaluation.

Preventive Dosage (Powder): 300 mg orally once a day, 30 minutes before meals, 5 days a week for 4 weeks, with courses repeated 2–3 times a year for chronic prostatitis in remission, initial stage vascular erectile dysfunction, and pelvic venous congestion in men over 40 years.

Pediatric Dosage (Powder): Do not use in children and adolescents under 18 years; no scientific data on safe dosage in children have been registered.

Contraindications (Powder): Photodermatitis, photosensitivity, use of photosensitizing drugs, severe hepatic insufficiency, individual hypersensitivity; no scientific data on contraindications during pregnancy, lactation, and in childhood have been registered.

Side Effects (Powder): In case of overdose, phototoxic dermatitis, nausea, dyspepsia, and dizziness are possible.

Adjustment for Patient Body Weight (Powder): For body weight below 60 kg, reduce the daily dose by 25%; for body weight 60–90 kg, use standard regimens; for body weight over 90 kg, increase the daily dose by 20% if tolerated.

Preparation method (Powder): Raw material — roots; for 100 grams of product: dried roots 100 grams. Collection of mature roots, mechanical removal of soil, washing with running water, cutting into fragments of 3–5 millimeters, drying at a temperature of 35–40 degrees Celsius to a residual moisture content of no more than ten percent, stepwise grinding to a fraction of 300–500 micrometers, sieving, dust removal with a cyclone separator, repeated moisture control, packaging in airtight containers with a moisture absorber. No additives are used.

Storage Conditions and Shelf Life (Powder): Store in tightly closed dark glass or metallized polymer containers at a temperature of 5 to 25 degrees Celsius, protect from direct light, moisture, and sources of electromagnetic interference; shelf life up to twenty-four months; after opening, use within six months under conditions of minimal air contact.

Dry Extract — Peucedanum morisonii

Indications (Dry Extract): Chronic non-bacterial prostatitis, congestive prostatitis, chronic pelvic pain syndrome, chronic vesiculitis, prostatodynia, initial stage vascular erectile dysfunction.

Standard Dosage (Dry Extract): 150–250 mg orally 1–2 times a day before meals, course of 21–30 days.

Enhanced Dosage (Dry Extract): 300–400 mg orally 1–2 times a day before meals for pronounced pain syndrome, chronic prostato-vesiculitis, and pelvic venous congestion; course of 30–45 days.

Maximum Dosage (Dry Extract): Up to 500 mg orally 2 times a day (up to 1 gram per day) for no more than fourteen days for resistant chronic pelvic pain syndrome; further use based on clinical evaluation.

Preventive Dosage (Dry Extract): 150 mg orally once a day, 30 minutes before meals, five days a week for four weeks, with courses repeated two to three times a year for chronic prostatitis in remission and initial stage vascular erectile dysfunction in men over forty years.

Pediatric Dosage (Dry Extract): Do not use in children and adolescents under eighteen years; no scientific data on safe dosage in children have been registered.

Contraindications (Dry Extract): Photodermatitis, photosensitivity, use of photosensitizing drugs, severe hepatic insufficiency, individual hypersensitivity; no scientific data on contraindications during pregnancy, lactation, and in childhood have been registered.

Side Effects (Dry Extract): In case of overdose, phototoxic dermatitis, nausea, dyspepsia, and dizziness are possible.

Adjustment for Patient Body Weight (Dry Extract): For body weight below 60 kilograms, reduce the daily dose by twenty-five percent; for body weight 60–90 kilograms, use standard regimens; for body weight over 90 kilograms, increase the daily dose by twenty percent if tolerated.

Preparation method (Dry Extract): To obtain 100 grams of finished product, use dried roots 500 grams, purified water 250 milliliters, 95% food-grade ethyl alcohol 250 milliliters. Extraction by maceration in a 50% by volume water-ethanol mixture at a temperature of 25–30 degrees Celsius for seventy-two hours with daily stirring, filtration through a paper filter, repeated extraction of the raw material with the same solution for forty-eight hours, combining the extracts. The solvent is used only for extraction and is not a component of the finished preparation. Complete removal of the solvent: evaporation in a water bath at a temperature not exceeding fifty degrees Celsius to a thick extract, then vacuum evaporation to a dry residue. The control indicator of removal is the complete disappearance of the alcohol odor. The permissible residual ethanol content in the finished product is no more than five thousand parts per million for oral use in accordance with pharmacopoeial standards of class three. Warning: toxicity of the organic solvent, inadmissibility of using the intermediate product with liquid solvent as a medicinal product. Grind the dry extract to a homogeneous fraction, package in portions.

Storage Conditions and Shelf Life (Dry Extract): Store in airtight dark glass or metallized polymer containers at a temperature of 5 to 25 degrees Celsius, protect from light, moisture, and sources of electromagnetic interference; shelf life up to twenty-four months; after opening, use within six months under conditions of protection from air.

Alcohol-Based Tincture — Peucedanum morisonii

Indications (Tincture): Chronic non-bacterial prostatitis, congestive prostatitis, chronic pelvic pain syndrome, chronic vesiculitis, prostatodynia, initial stage vascular erectile dysfunction, chronic prostato-vesiculitis, orchiepididymitis.

Standard Dosage (Tincture): 3–5 milliliters of tincture 2 times a day before meals, course of 21–30 days.

Enhanced Dosage (Tincture): 5 milliliters of tincture 3 times a day for chronic prostatitis with pronounced pain syndrome, chronic vesiculitis, and vascular erectile dysfunction; course of 30–45 days.

Maximum Dosage (Tincture): Up to 10 milliliters of tincture 2 times a day (up to 20 milliliters per day) for no more than ten days for exacerbation of chronic prostato-vesiculitis and pronounced pelvic pain; further use based on clinical observation.

Preventive Dosage (Tincture): 3 milliliters of tincture once a day, thirty minutes before meals, five days a week for four weeks, with courses repeated two to three times a year for chronic prostatitis in remission, initial stage vascular erectile dysfunction, and prostatorrhea.

Pediatric Dosage (Tincture): Do not use in children and adolescents under eighteen years; no scientific data on safe dosage in children have been registered.

Contraindications (Tincture): Photodermatitis, photosensitivity, use of photosensitizing drugs, severe hepatic insufficiency, alcohol dependence, individual hypersensitivity; no scientific data on contraindications during pregnancy, lactation, and in childhood have been registered.

Side Effects (Tincture): In case of overdose, phototoxic dermatitis, nausea, headache, drowsiness, and mild gastric mucosal irritation are possible.

Adjustment for Patient Body Weight (Tincture): For body weight below 60 kilograms, reduce the daily dose by twenty-five percent; for body weight above 90 kilograms, increase the daily dose by twenty percent if tolerated.

Preparation method (Tincture): To obtain 100 milliliters of finished tincture, use dried ground roots 20 grams, 50% by volume food-grade ethyl alcohol 100 milliliters. Place the roots in a glass container, pour with alcohol, close with an airtight lid, keep at a temperature of 20–25 degrees Celsius in a dark place for forty days with daily stirring. After maceration, filter, squeeze the residue, combine the extracts. The solvent is used only as an extractant and is not a component of the finished preparation. Control of alcohol removal is not required, as the ethanol concentration in the tincture is constant. If concentration is necessary, evaporate in a water bath at a temperature not exceeding fifty degrees Celsius to half the volume. Package in dark glass bottles.

Storage Conditions and Shelf Life (Tincture): Store in tightly closed dark glass containers at a temperature of 5 to 25 degrees Celsius, protect from direct light and heat sources; shelf life up to thirty-six months; after opening, use within six months.

Oil Infusion — Peucedanum morisonii

Indications (Oil Infusion): Chronic non-bacterial prostatitis, congestive prostatitis, chronic pelvic pain syndrome, prostato-vesiculitis, orchiepididymitis, urethroprostatic pain syndrome, mild dysuria.

Standard Dosage (Oil Infusion): Externally apply 2–3 milliliters of infusion to the perineal area and lower abdomen 1–2 times a day with light rubbing movements, course of 21–30 days.

Enhanced Dosage (Oil Infusion): 3–4 milliliters of infusion applied to the perineal and sacral area 2 times a day for pronounced pain and congestive processes in the pelvis; course of 30–45 days.

Maximum Dosage (Oil Infusion): Up to 5 milliliters 2 times a day (10 milliliters per day) for no more than ten days for exacerbation of pelvic pain and congestive phenomena; then switch to standard dosage.

Preventive Dosage (Oil Infusion): 2 milliliters of infusion applied to the perineal area once a day for ten days monthly for chronic prostatitis in remission and prostato-vesiculitis; recommended for men over forty years with a sedentary lifestyle.

Pediatric Dosage (Oil Infusion): External use in adolescents over fifteen years is possible at a dosage of up to 1 milliliter once a day; for younger ages, no safety data have been registered.

Contraindications (Oil Infusion): Individual hypersensitivity, dermatitis, skin damage in the application area, photosensitivity; no data on contraindications during pregnancy and lactation have been registered.

Side Effects (Oil Infusion): In case of overdose, skin irritation, mild redness, and photosensitization are possible.

Adjustment for Patient Body Weight (Oil Infusion): Adjustment is not required; the dosage is selected based on the area of application.

Preparation method (Oil Infusion): To prepare 100 grams of product, use ground dried roots 20 grams, coconut oil 100 milliliters. Place the raw material in a glass container, pour with coconut oil, keep in a water bath at a temperature of 60 degrees Celsius for 4 hours, then infuse at a temperature of 25 degrees Celsius for forty-eight hours. Filter, squeeze the residue, filter again. Store the finished infusion in a dark container; do not use solvents or chemical additives.

Storage Conditions and Shelf Life (Oil Infusion): Store in hermetically sealed dark glass containers at a temperature of 5 to 20 degrees Celsius, protect from light and heat sources; shelf life up to eighteen months; after opening, use within three months.

Ointment — Peucedanum morisonii

Indications (Ointment): Chronic non-bacterial prostatitis, congestive prostatitis, chronic pelvic pain syndrome, prostato-vesiculitis, orchiepididymitis, pudendal neuralgia, venous congestion of the pelvic organs.

Standard Dosage (Ointment): Apply to the perineal, sacral, and lower abdominal area in a thin layer 1–2 times a day, course of 21–30 days.

Enhanced Dosage (Ointment): Apply 2–3 times a day for pronounced pain, neuralgia, congestive processes, and orchiepididymitis, combine with mild thermal exposure; course of 30–45 days.

Maximum Dosage (Ointment): Up to 3–4 times a day for ten days for exacerbation of chronic prostato-vesiculitis and pronounced pain syndrome, then switch to the standard regimen.

Preventive Dosage (Ointment): Apply once a day for 10 days monthly for chronic prostatitis in remission, pelvic venous congestion, and chronic orchiepididymitis.

Pediatric Dosage (Ointment): External use in adolescents over fifteen years is possible at a dose of no more than 1 gram of ointment once a day; for younger ages, no safety data have been registered.

Contraindications (Ointment): Individual hypersensitivity, dermatitis, skin damage, photosensitivity, inflammatory dermatoses; no data on contraindications during pregnancy and lactation have been registered.

Side Effects (Ointment): In case of overdose, redness, itching, skin irritation, and photosensitization are possible.

Adjustment for Patient Body Weight (Ointment): Not required; the dosage is selected based on the area of application.

Preparation method (Ointment): For 100 grams of finished product: oil infusion of Morison's hog's fennel 30 grams, purified beeswax 10 grams, coconut oil 60 grams. Water bath at 60 degrees Celsius, melt the wax and coconut oil, add the oil infusion, mix thoroughly until homogeneous, cool to 40 degrees Celsius, pour into sterile jars. No synthetic preservatives added. No residual organic solvents.

Storage Conditions and Shelf Life (Ointment): Store in dark airtight containers at a temperature of 5 to 20 degrees Celsius, avoid heating and direct sunlight; shelf life 12 months; after opening, use within 3 months.

Cream — Peucedanum morisonii

Indications (Cream): Congestive prostatitis, chronic pelvic pain syndrome, chronic prostato-vesiculitis, orchiepididymitis, neurovascular dysfunction, venous congestion of the pelvic organs.

Standard Dosage (Cream): Apply to the perineal, sacral, and lower abdominal area 1–2 times a day, course of 21–30 days.

Enhanced Dosage (Cream): Apply 2–3 times a day for pronounced congestive phenomena, pain syndrome, and decreased microcirculation; course of 30–45 days.

Maximum Dosage (Cream): Up to 3–4 applications per day for 7–10 days for pronounced pain, then switch to standard dosage.

Preventive Dosage (Cream): Apply once a day for 10 days monthly for chronic prostatitis in remission and vascular erectile dysfunction.

Pediatric Dosage (Cream): External use in adolescents over fifteen years is possible at a dosage of no more than 1 milliliter of cream once a day; for younger ages, no safety data have been registered.

Contraindications (Cream): Individual hypersensitivity, dermatitis, skin damage, photosensitivity, inflammatory dermatoses; no data on contraindications during pregnancy and lactation.

Side Effects (Cream): In case of overdose, skin irritation, itching, redness, burning sensation, and photosensitization are possible.

Adjustment for Patient Body Weight (Cream): Not required.

Preparation method (Cream): For 100 grams of finished product: oil infusion of Morison's hog's fennel 25 grams, coconut oil 30 grams, distilled water 40 grams, natural emulsifier (beeswax or lecithin) 5 grams. Heat the oil and emulsifier to 60 degrees Celsius, introduce the aqueous phase with constant stirring, cool to 40 degrees, add the oil infusion, mix thoroughly until homogeneous. Do not use solvents. The product does not contain synthetic stabilizers.

Storage Conditions and Shelf Life (Cream): Store in airtight dark glass containers at a temperature of 5 to 20 degrees Celsius, avoid sunlight and overheating; shelf life 9 months; after opening, use within 60 days.

Essential Oil — Peucedanum morisonii

Indications (Essential Oil): Chronic non-bacterial prostatitis, congestive prostatitis, chronic pelvic pain syndrome, prostato-vesiculitis, vascular erectile dysfunction, pudendal neuralgia, venous congestion of the pelvic organs, mild androgenic dysfunction.

Standard Dosage (Essential Oil): 2–3 drops of essential oil in 10 milliliters of carrier oil for external massage or aroma compresses, 1–2 times a day, course of 21–30 days.

Enhanced Dosage (Essential Oil): 3–4 drops of essential oil in 10 milliliters of carrier oil for massage or applications in the perineal, sacral, and lumbar areas for chronic prostato-vesiculitis and congestive phenomena; course of 30–45 days.

Maximum Dosage (Essential Oil): Up to 5 drops of essential oil in 10 milliliters of carrier oil 2 times a day for no more than ten days for exacerbation of pain syndrome and vascular congestion of the pelvis, then switch to standard dosage.

Preventive Dosage (Essential Oil): 2 drops of essential oil in 10 milliliters of carrier oil for massage once a day for ten days monthly for chronic prostatitis in remission, orchiepididymitis, and prostatorrhea.

Pediatric Dosage (Essential Oil): Do not use in children under fifteen years; in adolescents over fifteen, external use is permissible at a concentration of no more than one drop of essential oil per 10 milliliters of carrier oil.

Contraindications (Essential Oil): Photosensitivity, photodermatosis, individual intolerance, dermatitis, inflammatory skin diseases, pregnancy, lactation.

Side Effects (Essential Oil): In case of overdose, skin irritation, photosensitization, headache, nausea, and drowsiness are possible.

Adjustment for Patient Body Weight (Essential Oil): For body weight below 60 kilograms, reduce the concentration of essential oil by one drop per 10 milliliters of carrier oil; for body weight above 90 kilograms, an increase in concentration by one drop is permissible if tolerated.

Preparation method (Essential Oil): To obtain 100 milliliters of essential oil, 10 kilograms of fresh ground roots or herb are used. The raw material is subjected to steam distillation for 4–5 hours at a temperature of 98–100 degrees Celsius. The condensate is collected, separated into aqueous and oil phases, the essential oil is separated and dried over anhydrous sodium sulfate. Organic solvents are not used. The finished product is packaged in dark glass bottles with tight stoppers.

Storage Conditions and Shelf Life (Essential Oil): Store in airtight dark glass bottles at a temperature of 5 to 20 degrees Celsius, protect from light, heat, and moisture; shelf life up to twenty-four months; after opening, use within six months.

Decoction — Peucedanum morisonii

Indications (Decoction): Chronic non-bacterial prostatitis, congestive prostatitis, prostato-vesiculitis, orchiepididymitis, mild dysuria, urethral inflammation, chronic pelvic pain syndrome, prostatodynia.

Standard Dosage (Decoction): 100 milliliters of decoction 2 times a day before meals, course of 21–30 days.

Enhanced Dosage (Decoction): 150 milliliters of decoction 2–3 times a day for chronic prostato-vesiculitis, orchiepididymitis, and congestive phenomena; course of 30–45 days.

Maximum Dosage (Decoction): 200 milliliters of decoction 2 times a day (up to 400 milliliters per day) for no more than ten days for pronounced inflammation and pain syndrome; then switch to standard regimen.

Preventive Dosage (Decoction): 100 milliliters of decoction once a day, five days a week for four weeks, with courses repeated two to three times a year for chronic prostatitis in remission, pelvic venous congestion, and neurogenic dysuria.

Pediatric Dosage (Decoction): 10 milliliters of decoction 2 times a day for children over twelve years for mild inflammatory processes of the urinary tract; for younger ages, no safety data exist.

Contraindications (Decoction): Photosensitivity, photodermatitis, individual intolerance, severe hepatic insufficiency; no data on contraindications during pregnancy and lactation.

Side Effects (Decoction): In case of overdose, dyspepsia, nausea, diarrhea, and mild gastric irritation are possible.

Adjustment for Patient Body Weight (Decoction): For body weight below 60 kilograms, reduce the volume of intake by 25 percent; for body weight above 90 kilograms, increase by 20 percent.

Preparation method (Decoction): For 1000 milliliters of decoction, use dried ground roots 20 grams, purified water 1000 milliliters. Place the raw material in an enamel container, pour with water at room temperature, keep for one hour, then boil over low heat for 15 minutes, infuse for 30 minutes at room temperature, strain, squeeze the residue, bring the volume with boiled water to the original level. Do not use solvents.

Storage Conditions and Shelf Life (Decoction): Store in the refrigerator at a temperature of 4 to 8 degrees Celsius for no more than three days; do not allow freezing or heating; warm to a temperature of 36–38 degrees Celsius before use.

Liqueur Tincture (Alcoholic Macerate) — Peucedanum morisonii

Indications (Liqueur Tincture): Chronic non-bacterial prostatitis, congestive prostatitis, prostato-vesiculitis, vascular erectile dysfunction, chronic pelvic pain syndrome, prostatodynia, chronic orchiepididymitis.

Standard Dosage (Liqueur Tincture): 10–15 milliliters of liqueur tincture orally once a day after meals, course of 21–30 days.

Enhanced Dosage (Liqueur Tincture): 15–20 milliliters of liqueur tincture 1–2 times a day for chronic prostato-vesiculitis, congestive phenomena, and vascular erectile dysfunction; course of 30–45 days.

Maximum Dosage (Liqueur Tincture): Up to 25 milliliters of liqueur tincture 2 times a day (50 milliliters per day) for no more than ten days for pronounced vascular insufficiency and pain syndrome.

Preventive Dosage (Liqueur Tincture): 10 milliliters of liqueur tincture once a day after meals, five days a week for four weeks, with courses repeated twice a year in men over forty years for chronic prostatitis in remission and pelvic venous congestion.

Pediatric Dosage (Liqueur Tincture): Do not use in children and adolescents under eighteen years.

Contraindications (Liqueur Tincture): Alcoholism, liver diseases, photodermatitis, photosensitivity, individual intolerance, use of photosensitizing drugs; no data on contraindications during pregnancy and lactation.

Side Effects (Liqueur Tincture): In case of overdose, dizziness, nausea, mild gastric irritation, and photosensitization are possible.

Adjustment for Patient Body Weight (Liqueur Tincture): For body weight below 60 kilograms, reduce the dose by 25 percent; for body weight above 90 kilograms, increase by 20 percent if tolerated.

Preparation method (Liqueur Tincture): To obtain 1000 milliliters of finished product, use ground dried roots 200 grams, 40% food-grade ethyl alcohol 700 milliliters, natural honey 200 grams, purified water 100 milliliters. Place the roots in a glass container, add honey and the alcohol-water mixture, mix thoroughly, infuse at a temperature of 20–25 degrees Celsius for 40 days in a dark place, shaking daily. Upon completion of maceration, filter, squeeze the residue, keep the finished tincture for another 7 days at a temperature of 10–15 degrees Celsius, pour into dark bottles. Ethyl alcohol is used as an extractant and a component of the finished preparation. Do not add preservatives or flavorings.

Storage Conditions and Shelf Life (Liqueur Tincture): Store in tightly closed dark glass containers at a temperature of 5 to 20 degrees Celsius, protect from direct light; shelf life up to 36 months; after opening, use within 6 months.

Glycerin Macerate — Peucedanum morisonii

Indications (Glycerin Macerate): Chronic non-bacterial prostatitis, chronic pelvic pain syndrome, prostato-vesiculitis, orchiepididymitis, prostatodynia, neurogenic dysuria, urethral inflammation.

Standard Dosage (Glycerin Macerate): 5 milliliters orally 2 times a day before meals, course of 21–30 days.

Enhanced Dosage (Glycerin Macerate): 7 milliliters 2 times a day for pronounced pain syndrome and pelvic congestive processes; course of 30–45 days.

Maximum Dosage (Glycerin Macerate): 10 milliliters 2 times a day (up to 20 milliliters per day) for no more than ten days for pronounced inflammation or pain syndrome.

Preventive Dosage (Glycerin Macerate): 5 milliliters once a day, 5 days a week for four weeks, with courses repeated 2–3 times a year for chronic prostatitis in remission.

Pediatric Dosage (Glycerin Macerate): 2 milliliters orally once a day for children over 12 years for mild inflammations of the urinary tract; for younger ages, no safety data exist.

Contraindications (Glycerin Macerate): Diabetes mellitus, individual intolerance, photodermatitis, photosensitivity, severe hepatic insufficiency; no data on contraindications during pregnancy and lactation.

Side Effects (Glycerin Macerate): In case of overdose, mild nausea, flatulence, diarrhea, and drowsiness are possible.

Adjustment for Patient Body Weight (Glycerin Macerate): For body weight below 60 kilograms, reduce the dose by 25 percent; for body weight above 90 kilograms, increase by 20 percent if tolerated.

Preparation method (Glycerin Macerate): To obtain 100 milliliters of finished product, use dried ground roots 20 grams, vegetable glycerin 60 milliliters, purified water 40 milliliters. Mix glycerin and water, heat to 40 degrees Celsius, add the plant raw material, mix thoroughly, keep at a temperature of 25–30 degrees Celsius for 21 days, shaking daily. After maceration, filter, squeeze the residue, filter again, pour into dark bottles. Do not use organic solvents. Do not add preservatives.

Storage Conditions and Shelf Life (Glycerin Macerate): Store in airtight dark glass containers at a temperature of 5 to 20 degrees Celsius, protect from light; shelf life up to 12 months; after opening, use within 3 months.

Fumigation (Smoking) — Peucedanum morisonii

Indications (Fumigation): Chronic non-bacterial prostatitis, congestive prostatitis, chronic pelvic pain syndrome, prostato-vesiculitis, pelvic venous congestion, vascular erectile dysfunction, urethral inflammation, chronic orchiepididymitis, prostatodynia, pelvic neurovascular dysfunction.

Standard Dosage (Fumigation): Fumigation sessions once a day lasting 10–15 minutes, course of 14–21 days, use 3–4 grams of dried plant raw material per session.

Enhanced Dosage (Fumigation): Fumigation sessions 2 times a day for 10–15 minutes for pronounced pain, congestive phenomena, and chronic inflammation of the pelvic organs; course of 21–30 days.

Maximum Dosage (Fumigation): 2 sessions of 20 minutes per day (up to 8 grams of raw material per day) for no more than 10 days in a row for pronounced pain syndrome and congestive venous congestion of the pelvic organs; then switch to standard dosage.

Preventive Dosage (Fumigation): 1 fumigation session lasting 10 minutes every 3–4 days for one month in men over forty years for chronic prostatitis in remission and pelvic congestive processes.

Pediatric Dosage (Fumigation): Do not use in children and adolescents under 18 years; no safety data for this age category have been registered.

Contraindications (Fumigation): Bronchial asthma, chronic obstructive pulmonary disease, acute inflammatory diseases of the respiratory tract, photosensitivity, individual intolerance to the smell of essential oils; no data on contraindications during pregnancy and lactation.

Side Effects (Fumigation): In case of overdose, dizziness, irritation of the mucous membranes of the eyes and respiratory tract, mild palpitations, and drowsiness are possible.

Adjustment for Patient Body Weight (Fumigation): Not required; the procedure is performed in standard volumes regardless of body weight.

Preparation method (Fumigation): For one session, use 3–4 grams of dry ground roots or herb of Morison's hog's fennel. Grind the raw material to a fraction of 2–3 millimeters, distribute evenly on a metal or ceramic saucer, place on a heat source (coal or electric plate), heat until light smoke appears. The smoldering temperature should be 180–220 degrees Celsius. The patient is positioned at a distance of 30–40 centimeters from the smoke source in a sitting position, in a room with minimal ventilation. Preparation is carried out without the use of solvents and chemical additives. After the procedure, ventilate the room.

Storage Conditions and Shelf Life (Fumigation): Store dried raw material in tightly closed dark glass or metallized polymer containers at a temperature of 5 to 25 degrees Celsius, protect from moisture and light; shelf life up to 24 months; after opening, use within 6 months.

Toxicity and Biosafety of Peucedanum morisonii

For the species Peucedanum morisonii, no LD₅₀ data are available in accessible referenced sources; safety assessment is based on the toxicology of the main components of the genus (furanocoumarins — 8-methoxypsoralen/xanthotoxin, 5-methoxypsoralen/bergapten). For 8-methoxypsoralen, wide ranges of acute toxicity in rodents are reported: mice and rats upon oral administration — LD₅₀ approximately 200–4000 mg/kg body weight (depending on the form and route of administration); for 5-methoxypsoralen: mice ~8100 mg/kg p.o., rats >30,000 mg/kg p.o., guinea pigs ~505 mg/kg p.o. Furanocoumarins exhibit phototoxicity (enhanced under UV-A), with proven genotoxic and photocarcinogenic risks when combined with UV irradiation; without UV light exposure, toxicity is significantly lower. According to WHO/EFSA criteria for acute oral toxicity, such values correspond to the range of "low-toxic—moderately toxic" (depending on the specific compound and model), while the key risk of the taxon is phototoxicity and possible genotoxicity under UV-A. It is recommended to exclude UV irradiation of the skin/mucous membranes during the intake period and to consider medicinal photosensitizers.

References:

- Quetglas-Llabrés M.M. et al., 2022. Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Insights. Biomolecules 12(5):720. (https://pmc.ncbi.nlm.nih.gov/a...) PMC

- Wu A. et al., 2022. Xanthotoxin (8-methoxypsoralen): A review of its chemistry, pharmacology and toxicology. Phytochemistry Reviews. (https://pubmed.ncbi.nlm.nih.go...) PubMed

- SKLM/DFG, 2006. Toxicological Assessment of Furocoumarins in Foodstuffs. (значения LD₅₀ 8-MOP и 5-MOP; фототоксичность/генотоксичность) (https://www.dfg.de/resource/blob/169002/sklm-furocoumarine-en-2006.pdf) dfg.de

- Melough M.M. et al., 2017. Identification and Quantitation of Furocoumarins in Commonly Consumed Foods. J. Agric. Food Chem. 66(20):5307-5315. (данные о токсичности фуранокумаринов и роли УФ) (https://pmc.ncbi.nlm.nih.gov/articles/PMC8070520/) PMC

Pharmacodynamics — Peucedanum morisonii

The pharmacodynamic profile of the taxon is determined primarily by furanocoumarins (psoralen series: bergapten/5-methoxypsoralen, xanthotoxin/8-methoxypsoralen, etc.) and essential oil components (monoterpenes, etc.), typical of the genus Peucedanum. Linear furanocoumarins are capable of intercalating into DNA and, under ultraviolet-A irradiation, forming covalent mono- and diadducts with pyrimidine bases, accompanied by a block of replication and transcription. In the absence of UV-A, these compounds exhibit other biological effects related to the regulation of cellular signaling pathways: suppression of the transcription factor NF-κB, modification of MAPK cascades (ERK, JNK, p38), JAK/STAT and PI3K/AKT/mTOR, as well as activation of the antioxidant response through Nrf2/HO-1. Collectively, this leads to a decrease in the production of inflammatory mediators (prostanoids, nitric oxide under excessive iNOS induction, cytokines) and a reduction in oxidative stress at the tissue level.

For xanthotoxin, effects on mitochondrial and endoplasmic reticulum stress have been shown, accompanied by fine-tuning of apoptotic signals (Bax/Bcl-2, caspases) and regulation of reactive oxygen species; for bergapten, a complex of anti-inflammatory and antioxidant effects has been described, including a decrease in COX-2 expression and modulation of endothelial adhesion molecule expression. At the vascular level, for a number of furanocoumarins and related compounds, endothelium-dependent mechanisms of smooth muscle relaxation involving nitric oxide and potentiation of microcirculation have been shown; in the composition of essential oils, monoterpenes contribute to local hyperemia and trophic effects on the skin and underlying tissues with external use.

A significant pharmacodynamic feature of linear furanocoumarins is mechanism-based irreversible inhibition of the CYP3A4 isoenzyme in enterocytes of the small intestine. Covalent modification of the active center of CYP3A4 leads to a temporary loss of metabolic activity until the enzyme pool is restored, which must be taken into account with concomitant use of substrates of this isoenzyme. Along with CYP3A4, modulation of the activity of other cytochrome P450 enzymes (for example, CYP1A2) has been noted for some representatives of furanocoumarins, which affects the presystemic and systemic metabolism of xenobiotics.

In the immune system, furanocoumarins and accompanying phenolic components demonstrate effects on innate effector links (macrophages/monocytes) through a decrease in the production of TNF-α, IL-6, IL-1β and suppression of iNOS expression, as well as on adaptive reactions through indirect regulation of cytokine networks and stress response. At the level of the skin and mucous membranes, the photobiological component of action dominates: photosensitization followed by photochemical reactions in the presence of UV-A; with external use without UV load, local anti-inflammatory and antiseptic effects characteristic of monoterpenes and coumarins prevail.

Data on the genus Peucedanum indicate the presence of antispasmodic and myorelaxant potential with respect to smooth muscle structures, which is consistent with the pathways of influence on intracellular calcium, potassium channels, and vascular wall tone typical for coumarins and essential oil components; in parallel, moderate antimicrobial effects against gram-positive and gram-negative microorganisms have been described, associated with disruption of membrane integrity, inhibition of bacterial enzymes, and enhancement of oxidative stress in microbial cells. At the systemic level, the totality of these mechanisms forms an anti-inflammatory, antioxidant, vascular-modulating, and moderately immuno-regulatory effect, and in the presence of UV-A — a photobiological component with DNA-binding activity.

References:

- Quetglas-Llabrés M.M., et al. (2022). Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Insights. Biomolecules, 12(5):720. (https://pmc.ncbi.nlm.nih.gov/a...)

- Wu A., et al. (2022). Xanthotoxin (8-methoxypsoralen): A review of its chemistry, pharmacology, pharmacokinetics and toxicity. Phytotherapy Research. (https://pubmed.ncbi.nlm.nih.go...)

- Sarkhail P. (2014). Traditional uses, phytochemistry and pharmacological properties of the genus Peucedanum. Journal of Ethnopharmacology, 156:235–270. (https://pubmed.ncbi.nlm.nih.go...)

- Bailey D.G., et al. (2013). Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? CMAJ, 185(4):309–316. (https://pmc.ncbi.nlm.nih.gov/articles/PMC3589309/)

- Liu W., et al. (2020). Differences in xanthotoxin metabolites in seven mammalian species. Frontiers in Pharmacology, 11:1216. (https://pmc.ncbi.nlm.nih.gov/articles/PMC7444332/)

- Phucharoenrak P., et al. (2024). Bergaptol, a Major Furocoumarin in Citrus. Molecules, 29(3):682. (https://pmc.ncbi.nlm.nih.gov/articles/PMC10856120/)

- Guttman Y., et al. (2020). New grapefruit cultivars exhibit low cytochrome P4503A4-inhibiting furanocoumarins. Toxicology in Vitro, 67:104900. (https://www.sciencedirect.com/science/article/pii/S0278691520300223)

Pharmacokinetics — Peucedanum morisonii

Data on the pharmacokinetics of the specific taxon are limited; the description is based on the properties of its typical groups of substances and dosage forms. Upon oral administration, phenolic and coumarin-type components are absorbed in the small intestine with the participation of passive diffusion and transporters, after which they undergo pronounced presystemic transformation in the liver and enterocytes. They are characterized by a conjugation phase (mainly glucuronidation and sulfation), which forms predominantly water-soluble metabolites in plasma. Some compounds may be involved in enterohepatic circulation, prolonging the presence of metabolites in the systemic circulation. Intestinal microbiota participates in deglycosylation and reductive transformations of individual polyphenolic fractions with the formation of low molecular weight phenols suitable for subsequent conjugation and excretion.

Volatile components of the essential oil upon oral administration are rapidly absorbed from the upper parts of the gastrointestinal tract due to high lipophilicity and low molecular weight. They are distributed mainly in well-perfused tissues, with temporary accumulation in adipose and epidermal fractions, then undergo redox transformations and conjugation, which facilitates renal and biliary excretion. For the total complex of coumarin-like substances, the participation of hepatic microsomal enzymes and subsequent phase conjugation has been described; clinically significant drug interactions are associated with inhibition of enterohepatic and hepatic mechanisms of biotransformation, especially in the presence of food matrices with a high content of corresponding enzyme system inhibitors.

With transdermal use, bioavailability is determined by the ratio of lipophilicity and volatility, the state of the stratum corneum, and the composition of the base. Oil matrices rich in terpenes can increase skin permeability due to disorganization of the interlipid layers of the stratum corneum and improved dissolution of active substances in the skin lipid barrier. As a result, part of the volatile components reaches the dermis and local microcirculation with a predominance of local action; systemic exposure is usually limited and regulated by the area of application and contact time. The coumarin fraction penetrates the skin more slowly, however, with prolonged use, its accumulation in the superficial layers of the epidermis is possible, followed by metabolic detoxification in the skin and liver.

When applied to mucous membranes (oral, urogenital), absorption is accelerated due to bypassing part of the stratum corneum barriers and partial passage past presystemic metabolism, which increases the proportion of unchanged molecules, but simultaneously increases the requirements for monitoring concentrations and frequency of application. Inhalation of vapors or aerosols of the essential oil fraction ensures rapid entry through the alveolar membrane into the systemic circulation, short-term distribution in lung tissue and well-perfused organs, subsequent hepatic conjugation, and excretion with exhaled air, urine, and bile.

The main routes of elimination for water-soluble conjugates are the kidneys (with urine); for more lipophilic metabolites — bile with possible reabsorption in the intestine. The skin and lungs contribute to the excretion of volatile and semi-volatile components with external and inhalation use. Collectively, pharmacokinetics is determined by the dosage form (powder, tincture, extract, oil base), carrier matrix, and the state of barrier tissues; the participation of the liver and microbiota is key for transformations and clearance.

References:

- Manach C., Donovan J. (2004). Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radical Research, 38(8):771–785. (https://pubmed.ncbi.nlm.nih.gov/15493450/)

- Thilakarathna S.H., Rupasinghe H.P.V. (2013). Flavonoid Bioavailability and Attempts for Bioavailability Enhancement. Nutrients, 5(9):3367–3387. (https://pmc.ncbi.nlm.nih.gov/articles/PMC3798909/)

- Bailey D.G., Dresser G.K., Arnold J.M.O. (2013). Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? CMAJ, 185(4):309–316. (https://pmc.ncbi.nlm.nih.gov/articles/PMC3589309/)

- SCCP (2006). Opinion on Furocoumarins in cosmetic products. European Commission, SCCP/0942/05. (https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_036.pdf)

- Sapra B., Jain S., Tiwary A.K. (2008). Percutaneous Permeation Enhancement by Terpenes: A Review. Archives of Pharmacal Research, 31(11):1509–1519. (https://pmc.ncbi.nlm.nih.gov/articles/PMC2751457/)

- Kitahara M., et al. (1993). Evaluation of skin damage of cyclic monoterpenes, percutaneous absorption enhancers. Toxicology in Vitro, 7(6):791–796. (https://pubmed.ncbi.nlm.nih.gov/8268859/)

- SCCNFP (2001). Opinion concerning furocoumarins in sun protection and bronzing products. (https://ec.europa.eu/health/archive/ph_risk/committees/sccp/documents/out243_en.pdf)

Mechanisms of Action and Scientific Rationale — Peucedanum morisonii

The functional profile of the taxon is explained by the predominance of coumarin-like compounds (in particular linear furanocoumarin chromones) and the volatile fraction of the essential oil. At the cellular level, modulation of pro-inflammatory cascades NF-κB and MAPK (ERK, JNK, p38) with subsequent reduction of transcription of inflammatory mediators, as well as activation of the antioxidant response through the Nrf2/HO-1 pathway, are characteristic, accompanied by limitation of the formation of reactive oxygen species and stabilization of redox homeostasis. For a number of furanocoumarin components, effects on apoptosis-regulating nodes (Bcl-2/Bax balance, caspase cascades) and endoplasmic reticulum stress have been shown, leading to controlled initiation of programmed cell death under conditions of excessive activation of pro-inflammatory signals. At the level of vascular endothelium and smooth muscle structures, endothelium-dependent mechanisms of relaxation involving nitric oxide and secondary messengers have been described, as well as modulation of adhesion molecule expression, which mediates normalization of microcirculatory reactions. In the immune system, regulation of the production of key cytokines of the innate link (decrease in the release of TNF-α, IL-6, IL-1β; reduction of iNOS induction) and mediated influence on adaptive responses are noted. With respect to enzyme systems, coumarinoid structures can cause mechanism-based irreversible inactivation of intestinal and hepatic CYP3A4 isoenzyme and modify the activity of other cytochrome P450 isoforms, which explains known food and drug interactions upon oral exposure. For volatile monoterpenes of the essential oil, membranotropic effects on lipid domains of the plasmalemma and interlipid layers of the stratum corneum have been shown, accompanied by a change in barrier permeability and local microcirculation with transdermal use. The photobiological aspect of the mechanism is due to the ability of linear furanocoumarins to intercalate into DNA and, under the influence of ultraviolet-A, form mono- and diadducts with pyrimidine bases; without UV load, these same structures realize predominantly signal-regulatory and antioxidant pathways. The totality of the listed targets — transcription factors (NF-κB, Nrf2), signaling cascades (MAPK, PI3K/AKT), enzyme systems of biotransformation (cytochrome P450 isoenzymes), effector cells of innate immunity, endothelium, and vascular smooth muscles — forms systemic and local levels of action, explaining the anti-inflammatory, antioxidant, vasomodulating, and immuno-regulatory effects confirmed for representatives of the genus Peucedanum and their characteristic chemical classes.

References:

- Sarkhail P. (2014). Traditional uses, phytochemistry and pharmacological properties of the genus Peucedanum. Journal of Ethnopharmacology, 156:235–270. (https://pubmed.ncbi.nlm.nih.go...)

- Quetglas-Llabrés M.M., et al. (2022). Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Insights. Biomolecules, 12(5):720. (https://pmc.ncbi.nlm.nih.gov/a...)

- Wu A., et al. (2022). Xanthotoxin (8-methoxypsoralen): A review of its chemistry, pharmacology, pharmacokinetics, and toxicity. Phytotherapy Research, 36(10):3805–3832. (https://pubmed.ncbi.nlm.nih.go...)

- Bailey D.G., et al. (2013). Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? CMAJ, 185(4):309–316. (https://pmc.ncbi.nlm.nih.gov/articles/PMC3589309/)

- Guo L., et al. (2004). Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacologica Sinica, 25(2):129–136. (https://pubmed.ncbi.nlm.nih.gov/14769198/)

Synergy — Peucedanum morisonii

Data on synergy for the specific species are limited, however, for representatives of the genus Peucedanum and their predominant classes of compounds (linear coumarins/furanocoumarins and volatile monoterpenes), reproducible combinations confirmed in vitro and in vivo have been described. At the level of delivery through the skin, menthol (Mentha × piperita L.) and limonene (Citrus limon (L.) Osbeck/Citrus sinensis (L.) Osbeck) act as percutaneous penetrants, disorganizing the interlipid layers of the stratum corneum and increasing the dissolution of coumarins in the lipid barrier; this forms an additive and modulating effect in transdermal formulations with an oil base. In volatile compositions, the addition of thymol from Thymus vulgaris L. and carvacrol from Origanum vulgare L. demonstrates potentiation of the antimicrobial activity of essential oil mixtures due to membranotropic action and combined disruption of bacterial energy and enzymatic processes; the nature of the interaction is more often synergistic or at least additive. At the level of the antioxidant network, polyphenols of Camellia sinensis (L.) Kuntze (catechins) and ascorbate from Citrus limon replenish the "trapping" and regenerating links (radical-radical recombination and reduction of oxidized forms), which enhances the total antioxidant response of coumarin-containing compositions; for such combinations, both additive and potentiating effects have been described.

Pharmacokinetic synergy has been noted for the combination of furanocoumarin-containing taxa of the genus Peucedanum with piperine from Piper nigrum L.: suppression of conjugation enzyme systems and transporters in the intestine can enhance the oral systemic exposure of accompanying phenolic components, which is interpreted as a modulating/potentiating effect on bioavailability (shown for plant polyphenols; applicable by mechanism to the coumarin fraction). At the same time, pronounced inhibition of intestinal and hepatic metabolism by furanocoumarins (mechanism-based inactivation of biotransformation enzymes) is capable of potentiating the action of co-administered natural and synthetic substances, which forms pharmacokinetic synergy at the systemic level and requires consideration when designing multicomponent regimens. At the level of pro-inflammatory cascades, it has been shown that coumarin-type compounds in combination with polyphenols of Scutellaria baicalensis Georgi (baicalin/baicalein) and Glycyrrhiza glabra L. (phenolic flavonoids) provide convergent suppression of NF-κB/MAPK and enhancement of the antioxidant response, which manifests as an additive or potentiating anti-inflammatory and antioxidant effect in cellular models. For antibacterial strategies, synergy of coumarin derivatives with traditional antimicrobial agents and phytoconstituents (for example, phenolic terpenoids) has been substantiated through the combined disruption of membrane integrity, inhibition of bacterial enzymes, and redox imbalance; such combinations demonstrate a decrease in minimum inhibitory concentrations and a pronounced "protective" effect with respect to the formation of resistance. In transdermal bases on coconut oil (Cocos nucifera L.), the addition of monoterpenes (menthol, 1,8-cineole from Eucalyptus globulus Labill.) is described as a way to enhance local microcirculation and penetration of the coumarin fraction, forming tissue-specific synergy in the superficial and underlying layers. Collectively, such combinations provide systemic (oral forms), tissue (transdermal compositions), and cellular (in vitro) enhancement of anti-inflammatory, antioxidant, and antimicrobial directions of action with the correct selection of matrices and co-ingredients.

References:

- Sapra B., Jain S., Tiwary A.K. (2008). Percutaneous Permeation Enhancement by Terpenes: A Review. Archives of Pharmacal Research, 31(11):1509–1519. (https://pmc.ncbi.nlm.nih.gov/articles/PMC2751457/)

- Bassolé I.H.N., Juliani H.R. (2012). Essential oils in combination and their antimicrobial properties. Molecules, 17(4):3989–4006. (https://www.mdpi.com/1420-3049/17/4/3989)

- Shoba G., et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica, 64(4):353–356. (https://pubmed.ncbi.nlm.nih.gov/9619120/)

- Bailey D.G., et al. (2013). Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? CMAJ, 185(4):309–316. (https://pmc.ncbi.nlm.nih.gov/articles/PMC3589309/)

- Quetglas-Llabrés M.M., et al. (2022). Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Insights. Biomolecules, 12(5):720. (https://pmc.ncbi.nlm.nih.gov/a...)

- Zhao Q., et al. (2016). Scutellaria baicalensis Georgi: A Traditional Chinese Medicine with Modern Applications. Journal of Ethnopharmacology, 190:291–316. (https://pubmed.ncbi.nlm.nih.gov/27052711/)

- Hemaiswarya S., Doble M. (2009). Synergistic interaction of phenylpropanoids with antibiotics against Gram negative bacteria. Phytomedicine, 16(6–7): 586–592. (https://pubmed.ncbi.nlm.nih.gov/19339163/)

Geography of Use and Traditional Medicine — Peucedanum morisonii

The taxon is distributed mainly in Central and Eastern Europe, where it is found on dry meadows, forest edges, limestone slopes, and forest-steppe areas; it is noted in Poland, the Czech Republic, Slovakia, Germany (eastern regions), Austria, Hungary, Romania, the Balkans, the Baltic countries, western Ukraine, and the European part of Russia with foci in the forest-steppe zone. In the folk medicine of these regions, hog's fennel plants were traditionally classified as aromatic umbelliferous plants of a "bitter" profile, using mainly roots and fruits; forms of use included decoctions and aqueous infusions for internal and external use, alcohol infusions on homemade distillate or grape alcohol, powder from dried roots as a seasoning with a tonic taste, as well as oil macerates for rubbing and applications. In some local traditions of Eastern Europe, warm wraps made from ground roots mixed with warm vegetable oil were practiced, as well as fumigation with dried raw material in household and utility rooms as a way of "air purification" and livestock care in the cool season.

Ethnocultural contexts indicate a connection of hog's fennel plants with the "strength of the root" and the "bitterness of the field": in Slavic folk healing, roots were dried "on a heated stove," stored in linen bags, and a pinch was added to infusions "for strength." In the Carpathian area, rhizomes were included in seasonal collections of mountain herbs, which were infused on moonshine alcohol for winter use, while in Baltic and Central European villages, aqueous decoctions were used "for warmth" and rubbing with an oil base. At the household level, dried umbels were sometimes woven into protective wreaths and field bouquets, hung in attics and at entrances as "herb from bad air"; such practices were symbolic in nature and combined with seasonal rituals of collecting field herbs.

The historical depth of use is traced through mentions of the genus Peucedanum in European herbals of the early modern period, where bitter-spicy roots were described as suitable for infusions and warming rubs; specific attribution to the species Peucedanum morisonii is less common in old sources due to the similarity of morphological characters within the genus and frequent recording under generic or regional names. In the East Slavic and Central European manuscript tradition, a distinction was made between "field hog's fennel" and "forest hog's fennel," which reflected habitats and household forms of use of the raw material; in some localities, fruits were added to aromatic mixtures for bread and homemade liqueurs. Outside the European range, information on the targeted use of Peucedanum morisonii is isolated; in Asian traditions, other species of the genus are described in more detail (for example, species used in Chinese and Turkic herbals), which emphasizes the regional specificity of folk practice. In general, the cultural and ethnographic portrait of the taxon in Europe combines food-domestic, medicinal-domestic, and symbolic elements: decoctions and infusions were attributed with "strengthening bitterness," oil rubs were referred to as "warm" procedures, and smoke was considered a means of "purification" during periods of dampness and cold.